AstraZeneca invests $105 million in Harbour BioMed to collaborate on developing next-generation therapies for immune diseases and tumors.
Information on the Target
和铂医药控股有限公司 (Harbour BioMed) is a global biopharmaceutical company focused on the research and commercialization of innovative drugs, particularly in the fields of immune-related diseases and tumors. The company leverages its proprietary Harbour Mice® human antibody technology platform to develop next-generation bispecific antibody therapies targeting various diseases.
On March 21, 2023, Harbour BioMed announced a global strategic collaboration with AstraZeneca Holdings to jointly develop new therapies for immune diseases, tumors, and other conditions. This partnership includes a licensing agreement covering multiple projects based on Harbour's technology platform and a $105 million equity investment from AstraZeneca.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The biopharmaceutical sector in China is experiencing significant growth due to increased investment in research and development, supportive government policies, and a rising demand for innovative
Similar Deals
BeiGene, Ltd. → CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
2024
Sanofi → 天境生物 (TJ Biopharma)
2024
AstraZeneca Holdings
invested in
和铂医药
in 2025
in a Strategic Partnership deal
Disclosed details
Transaction Size: $105M